1 / 17

Legal Highs & Lows

Legal Highs & Lows. Clinical Experience of Novel Psychoactive Substances Dr Richard Stevenson. Background. Legal Highs -> Novel Psychoactive Substances 41 new substances in 2010 alone Diverse collection of compounds Piperazines Cathinones Synthetic cannabinoids Isolated compounds

murray
Download Presentation

Legal Highs & Lows

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Legal Highs & Lows Clinical Experience of Novel Psychoactive Substances Dr Richard Stevenson

  2. Background • Legal Highs -> Novel Psychoactive Substances • 41 new substances in 2010 alone • Diverse collection of compounds • Piperazines • Cathinones • Synthetic cannabinoids • Isolated compounds • Recreational problem identified in 2008/2009 • Varying legal status

  3. GRI Emergency Dept Experience • 12 AMT • 22 synthetic cannabinoids • 3 cathinone • 2 methoxetamine • 1 salvia • 9 life threatening toxicities

  4. Why are people taking them? • Legal status • Perception of safety • Difficult to detect • Point of care urine testing • Odourless • Availability • Internet • “Head shops” • Sold as other drugs

  5. AMT 5-IT

  6. Common Problems • Lack of reliable data • “Not what is says on the tin” • Dosage • Inter-individual variability • Time of onset to effect • Polysubstance misuse • Interactions ?

  7. Challenges in Clinical Care • Acute • Identification of xenobiotic • Lack of toxicological data • Mechanism of action • Duration • Clinical effects • Appropriate treatment • Chronic • Long term psychological effects • Long term physical effects

  8. Cathinones • Synthetic variations of natural cathinones in Khat • Mephedrone, methedrone, naphyrone • Ivory wave, meow-meow, bubbles, ocean snow, NRG • Sympathetic Toxidrome • ↑HR, RR, BP, temp • Tremor, agitation, paranoia, hallucinations, seizures • ***duration 24 – 48 hours*** • Treatments • Benzodiazepines +/- haloperidol

  9. Piperazines • Developed in 1950s – anti-helminthic agents • BZP “Benzo Fury” • Neurotransmitter release/reuptake inhibition • Phenylpiperazines • Direct serotonin receptor activation • Reversal of serotonin uptake • Clinically • Sympathetic toxidrome • Serotonin toxicity?

  10. Synthetic Cannabinoids • Annihilation, Black Mamba, Spice, K2 • Structurally dissimilar to THC • Herbal material sprayed with chemicals • Clinical effects • Nausea +++ • Collapse • Some psychotropic effects

  11. Methoextamine • Structurally similar to ketamine • NMDA receptor agonist • Clinically (dose related) • Excitation, tachycardia, euphoria • Hallucinations • Dissociation • Prolonged neurological effects - ataxia • Supportive management

  12. AMT/5-IT • AMT – Alphamethyltryptamine • 5-IT – 5-aminopropylindole • AMT researched as antidepressant in 1960’s • Non-specific MAOI • Hallucinations +++ • Psychomotor agitation +++ • Serotonin toxicity • High risk of toxicity

  13. Serotonin Toxicity • Exposure to a serotonergic drug • Clinical features • Confusion • Autonomic instability • Hyperkinetic musculoskeletal system

  14. Treatment of Serotonin Toxcity • Morbidity & Mortality related to hyperthermia • Temp ≥40 oC • Duration • Consequences • Rhabdomyolysis • Acute kidney injury • Acidosis • Cerebral damage

  15. Treatment of Serotonin Toxicity • Aggressive cooling • Antipyretics do not work! • Control muscular activity • High dose benzodiazepines • Haloperidol for severe non-responders • Appropriate fluid control • BP control agents • Anaesthesia with muscle paralysis

  16. The Future? • Market flooded with NPS • Difficult to legislate/control • Long term effects?

More Related